Beyond CA125/PSA

At Stage I Diagnostics, we believe that detection of cancer at its earliest stages offer the patient and physician the best opportunity to effectively treat the disease with the fewest adverse side effects. Being able to determine that an aggressive cancer is in development before clinical symptoms arise will lead to longer survival and better quality of life for patients. In addition to the diagnostic potential of our biomarkers, they hold the real possibility of being targets for future therapies which could be more effective than current protocols while producing far fewer and less severe side effects. At Stage I Diagnostics, we are working diligently to bring our full cancer diagnostic panel to market to fill this need and help make cancer a survivable disease.